phrykt

Theriva Biologics, Inc. (TOVX): who owns it and who trades it

As of Nov 12, 2026, no open-market insider purchases or sales of TOVX were reported in the last 12 months. 1 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 12, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Insider trades

No TOVX insider reported an open-market purchase or sale in the last 12 months.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$0
0 trades, 0 people
Sales under a 10b5-1 plan
–
Share of sale value
Latest trade
–
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

TOVX short interest

Low short interest. 3.1% of TOVX shares are sold short: about 1 share in 32. Over the last 12 reports the number of shares short went down 65%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 1.41M TOVX shares were sold short, 3.1% of the shares outstanding, down 23.4% from the report before. At the average daily volume of 516,671 shares, buying them all back would take about 2.7 trading days (days to cover).

Shares short, % of all shares

3.08%May 15Oct 309.71%

Days to cover

2.7May 15Oct 304.7

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20261.41M3.08%-23%516,6712.7
Oct 15, 20261.85M4.02%+8%560,6823.3
Sep 30, 20261.71M3.73%+8%439,2683.9
Sep 15, 20261.59M3.46%-10%508,0603.1
Aug 31, 20261.76M3.84%+3%577,6333.0
Aug 14, 20261.72M3.74%-19%528,8713.2
Jul 31, 20262.12M4.61%-9%500,9534.2
Jul 15, 20262.34M5.09%+61%4.50M1.0
Jun 30, 20261.45M3.17%-51%1.06M1.4
Jun 15, 20262.96M6.46%+9%28.29M1.0
May 29, 20262.72M5.94%-33%1.63M1.7
May 15, 20264.06M8.85%-52%3.05M1.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Theriva Biologics company events

Theriva Biologics filed 17 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 2, 2026.

  1. Nov 2, 2026DealThe information set forth in Item 1.01 of this Current Report on Form 8-K is incorporated by reference into this Item 2.01. Filing
  2. Aug 11, 2026ResultsReleased financial results. Filing
  3. Aug 6, 2026AnnouncementThe Company issued a press release announcing the dosing of the first patient in the VIRAGE2 clinical trial, a small proof-of-concept study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) in first-line metastatic PDAC patients treated with SoC… Filing
  4. Aug 4, 2026LeadershipTheriva Biologics, Inc. held its 2026 Annual Meeting of Stockholders. Filing
  5. Jul 7, 2026AnnouncementThe Company issued a press release announcing that the AEMPS has authorized the Company to initiate the VIRAGE2 clinical trial, entitled ”A Phase IIa, single-arm, single-center, open-label, proof-of-concept trial evaluating increased frequency dosing of zabilugene almadenorepvec (VCN-01) in… Filing
  6. Jun 11, 2026AnnouncementThe Company issued a press release announcing that clinical and translational results from VCN-01’s Phase 1 clinical trial in HNSCC were recently published on-line first in the journal Clinical Cancer Research. Filing
  7. Jun 5, 2026AnnouncementTheriva Biologics, Inc. called to order its Special Meeting of Stockholders. Filing
  8. May 5, 2026ResultsReleased financial results. Filing
  9. Apr 17, 2026AnnouncementThe Company issued a press release announcing an upcoming poster presentation of new data and subgroup analyses from the VIRAGE Phase 2b clinical trial evaluating VCN-01 (zabilugene almadenorepvec) plus gemcitabine/nab-paclitaxel in newly-diagnosed metastatic pancreatic cancer patients at the… Filing
  10. Apr 9, 2026AnnouncementTheriva Biologics, Inc. called to order its Special Meeting of Stockholders. Filing
  11. Mar 23, 2026AnnouncementThe Company issued a press release announcing the outcomes of a recent Type B End-of-Phase 2 (EOP2) meeting with the FDA regarding the design of a Phase 3 clinical study of lead clinical candidate VCN-01 in combination with standard-of-care chemotherapy for the treatment of PDAC. The FDA provided… Filing
  12. Mar 12, 2026ResultsReleased financial results. Filing
  13. Feb 18, 2026AgreementTheriva Biologics, Inc. entered into a license agreement with Rasayana Therapeutics, Inc., whereby the Company granted Rasayana an exclusive worldwide license with the right to grant sublicenses to Research, Develop, Manufacture and Commercialize (as such terms are defined in the Agreement) any… Filing
  14. Feb 12, 2026AnnouncementTheriva Biologics, Inc. called to order its Special Meeting of Stockholders. Filing
  15. Jan 12, 2026AnnouncementTheriva Biologics, Inc. will be making several presentations to investors over the next several weeks. Filing
  16. Dec 29, 2025AnnouncementThe Company issued a press release announcing receipt of Scientific Advice from the CHMP of the EMA on the design of a Phase 3 clinical trial of lead clinical candidate VCN-01 in combination with gemcitabine/nab-paclitaxel SoC chemotherapy for the first-line treatment of metastatic PDAC. The… Filing
  17. Dec 15, 2025AnnouncementTheriva Biologics, Inc. called to order its Special Meeting of Stockholders. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Theriva Biologics financials

Famous investors that hold TOVX

1 of the 50 well-known investors we track reported holding TOVX in their latest 13F filing. The largest position is Jim Simons's, worth $24.6K.

FundQuarterSharesValueOf portfolioChange
Jim Simons · Renaissance TechnologiesQ3 2026109,500$24.6K0.0%+72%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

Questions about Theriva Biologics, Inc. (TOVX) stock

Are TOVX insiders buying or selling?

No TOVX insider reported an open-market purchase or sale on Form 4 in the last 12 months. Share awards, option exercises and gifts are not counted.

What is the short interest in TOVX?

As of Oct 30, 2026, 1.41M TOVX shares were sold short, 3.1% of the shares outstanding, down 23.4% from the report before. At the average daily volume of 516,671 shares, buying them all back would take about 2.7 trading days (days to cover). See the history.

Which famous investors hold TOVX?

1 of the 50 well-known investors we track reported TOVX in their latest 13F filing, including Jim Simons. The largest position is worth $24.6K. See all holders.

Executive pay

Theriva Biologics's chief executive was paid a total of $903K for the year ended Dec 31, 2025, up 3% from $876K the year before. In the last 12 months, Theriva Biologics's executives and directors bought no stock on the open market and sold none.

Chief executive, total pay$903KYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$715KThe same year, with stock awards valued at what they were worth as they vested or at year end.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.